Insights from nanomedicine into chloroquine efficacy against COVID-19

被引：209
作者：
Hu, Tony Y. [1 ]
Frieman, Matthew [2 ]
Wolfram, Joy [3 ,4 ,5 ,6 ]
机构：
[1] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Cellular & Mol Diagnost, 1430 Tulane Ave, New Orleans, LA 70112 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA
[4] Mayo Clin, Dept Physiol & Biomed Engn, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Transplantat, Jacksonville, FL 32224 USA
[6] Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA
来源：
NATURE NANOTECHNOLOGY | 2020年 / 15卷 / 04期
基金：
美国国家卫生研究院;
关键词：
CORONAVIRUS; INFECTION; RECEPTOR; ENTRY; CELLS;
D O I：
10.1038/s41565-020-0674-9
中图分类号：
TB3 [工程材料学];
学科分类号：
0805 ; 080502 ;
摘要：
Chloroquine - an approved malaria drug - is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19.
引用
收藏
页码：247 / 249
页数：3
相关论文
共 23 条
[1]   Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model [J].
Dowall, Stuart D. ;
Bosworth, Andrew ;
Watson, Robert ;
Bewley, Kevin ;
Taylor, Irene ;
Rayner, Emma ;
Hunter, Laura ;
Pearson, Geoff ;
Easterbrook, Linda ;
Pitman, James ;
Hewson, Roger ;
Carroll, Miles W. .
JOURNAL OF GENERAL VIROLOGY, 2015, 96 :3484-3492
[2]   Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [J].
Gao, Jianjun ;
Tian, Zhenxue ;
Yang, Xu .
BIOSCIENCE TRENDS, 2020, 14 (01) :72-73
[3]  
Gentile E, 2013, FUTURE ONCOL, V9, P1849, DOI [10.2217/FON.13.146, 10.2217/fon.13.146]
[4]  
Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
[5]   Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors [J].
Hempelmann, Ernst .
PARASITOLOGY RESEARCH, 2007, 100 (04) :671-676
[6]   Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted [J].
Inoue, Yuuki ;
Tanaka, Nobuyuki ;
Tanaka, Yoshinori ;
Inoue, Shingo ;
Morita, Kouichi ;
Zhuang, Min ;
Hattori, Toshio ;
Sugamura, Kazuo .
JOURNAL OF VIROLOGY, 2007, 81 (16) :8722-8729
[7]   Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice [J].
Keyaerts, Els ;
Li, Sandra ;
Vijgen, Leen ;
Rysman, Evelien ;
Verbeeck, Jannick ;
Van Ranst, Marc ;
Maes, Piet .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) :3416-3421
[8]   Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus [J].
Li, WH ;
Moore, MJ ;
Vasilieva, N ;
Sui, JH ;
Wong, SK ;
Berne, MA ;
Somasundaran, M ;
Sullivan, JL ;
Luzuriaga, K ;
Greenough, TC ;
Choe, H ;
Farzan, M .
NATURE, 2003, 426 (6965) :450-454
[9]   Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro [J].
Liu, Jia ;
Cao, Ruiyuan ;
Xu, Mingyue ;
Wang, Xi ;
Zhang, Huanyu ;
Hu, Hengrui ;
Li, Yufeng ;
Hu, Zhihong ;
Zhong, Wu ;
Wang, Manli .
CELL DISCOVERY, 2020, 6 (01)
[10]   A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents [J].
Madrid, Peter B. ;
Chopra, Sidharth ;
Manger, Ian D. ;
Gilfillan, Lynne ;
Keepers, Tiffany R. ;
Shurtleff, Amy C. ;
Green, Carol E. ;
Iyer, Lalitha V. ;
Dilks, Holli Hutcheson ;
Davey, Robert A. ;
Kolokoltsov, Andrey A. ;
Carrion, Ricardo, Jr. ;
Patterson, Jean L. ;
Bavari, Sina ;
Panchal, Rekha G. ;
Warren, Travis K. ;
Wells, Jay B. ;
Moos, Walter H. ;
Burke, RaeLyn L. ;
Tanga, Mary J. .
PLOS ONE, 2013, 8 (04)
123